Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : GLS-1027
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
2nd Phase Clinical Trial of S. Korean Drug Firm's Covid-19 Treatment Candidate Approved in US
Details : The US Food and Drug Administration (FDA) have approved a phase two study of GLS-1027, an oral drug candidate known to prevent severe pneumonia caused by COVID-19 infection.
Product Name : GLS-1027
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 30, 2020
Lead Product(s) : GLS-1027
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
